

Reference:	FOI.8876.22
Subject:	Use of intra-vitreous injections or implants
Date of Request:	10 May 2022

Requested:

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from January to April 2022:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone acetonide
- Ranibizumab

2. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2022.

Number of injections/implants: Jan to Apr 2022

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration wAMD	Diabetic Macular Degeneration DMO	Retinal Vein Occlusion RVO
Aflibercept			
Bevacizumab			
Brolucizumab			
Dexamethasone			
Fluocinolone acetonide			
Ranibizumab			

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested for question 2, as it is estimated that the cost of answering your request would exceed the "appropriate limit" as stated in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. The "appropriate limit" represents the estimated cost of one person spending 18 hours (or 2½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with all of the data being requested, the UHB would need to undertake a manual search of all Ophthalmic patient records to identify the treatments administered during the requested period of January to April 2022, as this information is not recorded centrally.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under Section 16 of the FoIA, we are required as a public authority, to provide advice and assistance so far as it is reasonable, to individuals who have made a request under FoIA. Therefore, the UHB provides the information it holds for question 1 below.

1. The UHB provides, within the table overleaf, the number of each of the intra-vitreous injections/implants dispensed during the period January to April 2022.

Medication	Number
Aflibercept	2,438
Bevacizumab	0
Brolucizumab	5
Dexamethasone	28
Fluocinolone	21
Ranibizumab	2,325